Benzothiazole derivatives: novel inhibitors of methylglyoxal mediated glycation of proteins in vitro

Med Chem. 2014;10(8):824-35. doi: 10.2174/1573406410666140331230953.

Abstract

This manuscript describes the protein anti-glycation activity of thirty-three (33) benzothiazoles, out of which twenty-seven were the newly synthesized benzothiazoles. Compound 1 (IC50= 187 ± 2.6 µM) was found to be the most active, while compounds 2 (IC50= 219 ± 3.6 µM), 3 (IC50= 224 ± 1.9 µM), 4 (IC50= 223 ± 3.3 µM), 5 (IC50= 238 ± 2.2 µM), 7 (IC50= 266 ± 5.4 µM), 17 (IC50= 226 ± 1.6 µM) and 18 (IC50= 274 ± 2.4 µM) were significantly active, when compared with the standard rutin (IC50= 294 ± 1.5 µM). This study identified potential inhibitors of methylglyoxal mediated glycation of proteins, which is the pathophysiology of late diabetic complications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3 Cells
  • Animals
  • Benzothiazoles / chemical synthesis*
  • Benzothiazoles / chemistry
  • Benzothiazoles / pharmacology
  • Cattle
  • Cell Survival / drug effects
  • Chickens
  • Glycation End Products, Advanced / antagonists & inhibitors*
  • Glycation End Products, Advanced / chemistry
  • Glycosylation / drug effects
  • Mice
  • Muramidase / antagonists & inhibitors
  • Muramidase / chemistry
  • Pyruvaldehyde / chemistry*
  • Rutin / pharmacology
  • Serum Albumin, Bovine / antagonists & inhibitors
  • Serum Albumin, Bovine / chemistry
  • Structure-Activity Relationship

Substances

  • Benzothiazoles
  • Glycation End Products, Advanced
  • Serum Albumin, Bovine
  • Rutin
  • Pyruvaldehyde
  • Muramidase